- Home
- Automated
- List of product information
- A-LOSARTAN 100MG TABLETS [SIN13573P]
A-LOSARTAN 100MG TABLETS [SIN13573P]
Active ingredients: A-LOSARTAN 100MG TABLETS
Last updated 26 October 2025
Product Info
A-LOSARTAN 100MG TABLETS
[SIN13573P]
Product information
Active Ingredient and Strength | LOSARTAN POTASSIUM - 100 MG |
Dosage Form | TABLET, FILM COATED |
Manufacturer and Country | PHARMATHEN SA - GREECE |
Registration Number | SIN13573P |
Licence Holder | NOVEM PHARMA PRIVATE LIMITED |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | C09CA01 |
INDICATIONS
Treatment of hypertension.
DOSAGE & ADMINISTRATION
Usual starting and maintenance dose: 50 mg once daily with or without food. Some patients may receive an additional benefit by increasing the dose to 100 mg once daily.
Losartan may be administered with other antihypertensive agents.
The maximal antihypertensive effect is attained 3–6 weeks after initiation of therapy.
A starting dose of 25 mg once daily should be considered for patients with intravascular volume-depletion (e.g. those treated with high-dose diuretics) (see Precautions – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
No initial dosage adjustment is necessary for elderly patients up to 75 years of age or for patients with mild renal impairment. For patients above 75 years of age, patients with moderate to severe renal impairment and patients on dialysis, a lower starting dose of 25mg is recommended.
A lower dose should be considered for patients with a history of hepatic impairment (see Precautions – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
CONTRAINDICATIONS
Patients who are hypersensitive to any component of Losartan.
The concomitant use of Losartan with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73m2) (see Interactions – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).